Filing Flows › Lemaitre Vascular (LMAT) › R&D spending
Lemaitre Vascular (LMAT) R&D spending by quarter
Lemaitre Vascular's R&D spending was $4.4M in Q3 2026 (third quarter 2026), -9% from Q2 2026. Over the last 7 quarters it ranged from $3.0M (Q3 2025) to $4.8M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.4M | -9% | +49% |
| Q2 2026 | $4.8M | +19% | +37% |
| Q1 2026 | $4.1M | +15% | -0.9% |
| Q4 2025 | $3.5M | +19% | — |
| Q3 2025 | $3.0M | -16% | — |
| Q2 2025 | $3.5M | -14% | — |
| Q1 2025 | $4.1M | — | — |
Q3 2026 at a glance
Lemaitre Vascular, Q3 2026: revenue $68.0M (+11% year over year), operating margin 26.0%, net earnings $15.0M, operating cash flow $22.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Lemaitre Vascular's R&D spending?
Lemaitre Vascular's R&D spending was $4.4M in Q3 2026 (third quarter 2026), -9% from Q2 2026.
How has Lemaitre Vascular's R&D spending changed?
Over the last 7 quarters it ranged from $3.0M (Q3 2025) to $4.8M (Q2 2026).